We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Investigation of Strategies to Block Downstream Effectors of AT1R-Mediated Signalling to Prevent Aneurysm Formation in Marfan Syndrome.
- Authors
Valdivia Callejon, Irene; Buccioli, Lucia; Bastianen, Jarl; Schippers, Jolien; Verstraeten, Aline; Luyckx, Ilse; Peeters, Silke; Danser, A. H. Jan; Van Kimmenade, Roland R. J.; Meester, Josephina; Loeys, Bart
- Abstract
Cardiovascular outcome in Marfan syndrome (MFS) patients most prominently depends on aortic aneurysm progression with subsequent aortic dissection. Angiotensin II receptor blockers (ARBs) prevent aneurysm formation in MFS mouse models. In patients, ARBs only slow down aortic dilation. Downstream signalling from the angiotensin II type 1 receptor (AT1R) is mediated by G proteins and β-arrestin recruitment. AT1R also interacts with the monocyte chemoattractant protein-1 (MCP-1) receptor, resulting in inflammation. In this study, we explore the targeting of β-arrestin signalling in MFS mice by administering TRV027. Furthermore, because high doses of the ARB losartan, which has been proven beneficial in MFS, cannot be achieved in humans, we investigate a potential additive effect by combining lower concentrations of losartan (25 mg/kg/day and 5 mg/kg/day) with barbadin, a β-arrestin blocker, and DMX20, a C-C chemokine receptor type 2 (CCR2) blocker. A high dose of losartan (50 mg/kg/day) slowed down aneurysm progression compared to untreated MFS mice (1.73 ± 0.12 vs. 1.96 ± 0.08 mm, p = 0.0033). TRV027, the combination of barbadin with losartan (25 mg/kg/day), and DMX-200 (90 mg/kg/day) with a low dose of losartan (5 mg/kg/day) did not show a significant beneficial effect. Our results confirm that while losartan effectively halts aneurysm formation in Fbn1C1041G/+ MFS mice, neither TRV027 alone nor any of the other compounds combined with lower doses of losartan demonstrate a notable impact on aneurysm advancement. It appears that complete blockade of AT1R function, achieved by administrating a high dosage of losartan, may be necessary for inhibiting aneurysm progression in MFS.
- Subjects
ANGIOTENSIN-receptor blockers; MARFAN syndrome; CHEMOKINE receptors; ANGIOTENSIN II; ANEURYSMS; AORTIC aneurysms; AORTIC dissection
- Publication
International Journal of Molecular Sciences, 2024, Vol 25, Issue 9, p5025
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms25095025